Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy.
In this case report, we describe a 63-year-old female with Crohn's disease since age 16 years, and on adalimumab therapy, who inadvertently received a yellow fever vaccine (YFV) 4 days before her next dose of adalimumab. She had never received YFV. Her next dose of tumor necrosis factor (TNF) antagonist was held. She did not report any adverse effects referable to the vaccine. Reverse transcriptase-polymerase chain reaction (RT-PCR) for yellow fever (YF) viral RNA on days 12 and 18 postvaccination was negative. Neutralizing antibody to YF virus vaccine was immunoprotective on day 18 following vaccination, which further increased by day 26. A neutralizing antibody obtained 2 years following vaccination also remained immunoprotective.
Industrial Medical Center, Bridgeport Hospital, Bridgeport, CT, USA.
Esther R
ER
Nash
Division of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Myron
M
Brand
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Spyridon
S
Chalkias
D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D000914:Antibodies, Viral / Q000097:blood; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D007159:Immunologic Tests / Q000379:methods; D008875:Middle Aged; D014195:Travel; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000009:adverse effects; D015005:Yellow fever virus / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D000914:Antibodies, Viral; D022341:Yellow Fever Vaccine; D000068879:Adalimumab